Stock Analysis
- Sweden
- /
- Medical Equipment
- /
- OM:ACARIX
Acarix Second Quarter 2024 Earnings: kr0.02 loss per share (vs kr0.051 loss in 2Q 2023)
Acarix (STO:ACARIX) Second Quarter 2024 Results
Key Financial Results
- Revenue: kr1.96m (up 27% from 2Q 2023).
- Net loss: kr16.7m (loss narrowed by 24% from 2Q 2023).
- kr0.02 loss per share (improved from kr0.051 loss in 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Acarix Earnings Insights
Looking ahead, revenue is forecast to grow 83% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Medical Equipment industry in Sweden.
Performance of the Swedish Medical Equipment industry.
The company's shares are down 16% from a week ago.
Risk Analysis
Be aware that Acarix is showing 5 warning signs in our investment analysis and 2 of those are a bit unpleasant...
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OM:ACARIX
Acarix
A medical device company, develops solutions for rapid AI-based coronary artery disease (CAD) rule-out.